<DOC>
	<DOC>NCT00854100</DOC>
	<brief_summary>This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.</brief_summary>
	<brief_title>Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Men and women, 1865 years old Currently meet the DSMIVTR criteria for moderate to severe MDD without psychotic features. Previous failure to respond to adequate trials of one or two ADTs with less than 50% reduction in depressive symptoms during the present episode. DSMIVTR based diagnosis of an axis I disorder, other than MDD, or any axis I disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Adjunctive</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder (MDD)</keyword>
</DOC>